Original Study| Volume 19, ISSUE 8, P685-689, August 2018

SARC-F for Screening of Sarcopenia Among Older Adults: A Meta-analysis of Screening Test Accuracy



      To examine the screening ability of SARC-F for older adults using a meta-analysis.



      Setting and Participants

      The literature review was conducted using MEDLINE, Cochrane Database of Systematic Reviews, and Articles written on and after 1960 that included data regarding the sensitivity and specificity of SARC-F's diagnostic criteria for sarcopenia in older adults were searched.


      The bivariate random effects model was used to calculate the summary estimates of sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). The summary receiver operating characteristic curve was used to summarize the overall test performance.


      Seven studies involving a total of 12,800 subjects met the eligibility criteria of our study. The pooled results of sensitivity, specificity, PLR, NLR, and DOR with the European Working Group on Sarcopenia in Older People as the reference standard were 0.21 [95% confidence interval (CI), 0.13-0.31], 0.90 (95% CI, 0.83-0.94), 2.16 (95% CI, 1.51-3.09), 0.87 (95% CI, 0.80-0.95), and 2.47 (95% CI, 1.64-3.74), respectively. Overall, we achieved similar pooled results of sensitivity and specificity for studies using the International Working Group on Sarcopenia and Asian Working Group for Sarcopenia as the reference standards. Because few studies used the Foundation National Institute of Health reference standards, a meta-analysis was not performed.


      Although the screening sensitivity performance of SARC-F was poor, its specificity was high; thus, it is an effective tool for selecting subjects who should undergo further testing for confirming a diagnosis of sarcopenia.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Morley J.E.
        • Anker S.D.
        • von Haehling S.
        Prevalence, incidence, and clinical impact of sarcopenia: Facts, numbers, and epidemiology—update 2014.
        J Cachexia Sarcopenia Muscle. 2014; 5: 253-259
        • Morley J.E.
        Sarcopenia in the elderly.
        Fam Pract. 2012; 29: i44-i48
        • Kim H.
        • Suzuki T.
        • Kim M.
        • et al.
        Incidence and predictors of sarcopenia onset in community-dwelling elderly Japanese women: 4-year follow-up study.
        J Am Med Dir Assoc. 2015; 16: 85.e1-85.e8
        • Cruz-Jentoft A.J.
        • Baeyens J.P.
        • Bauer J.M.
        • et al.
        Sarcopenia: European consensus on definition and diagnosis: Report of the European working group on sarcopenia in older people.
        Age Ageing. 2010; 39: 412-423
        • Fielding R.A.
        • Vellas B.
        • Evans W.J.
        • et al.
        Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International working group on Sarcopenia.
        J Am Med Dir Assoc. 2011; 12: 249-256
        • Chen L.K.
        • Liu L.K.
        • Woo J.
        • et al.
        Sarcopenia in Asia: Consensus report of the Asian working group for sarcopenia.
        J Am Med Dir Assoc. 2014; 15: 95-101
        • McLean R.R.
        • Shardell M.D.
        • Alley D.E.
        • et al.
        Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: The foundation for the National Institutes of Health (FNIH) sarcopenia project.
        J Gerontol A Biol Sci Med Sci. 2014; 69: 576-583
        • Chang K.V.
        • Hsu T.H.
        • Wu W.T.
        • et al.
        Association between sarcopenia and cognitive impairment: A systematic review and meta-analysis.
        J Am Med Dir Assoc. 2016; 17 (1164.e7–1164.e15)
        • Chang K.V.
        • Hsu T.H.
        • Wu W.T.
        • et al.
        Is sarcopenia associated with depression? A systematic review and meta-analysis of observational studies.
        Age Ageing. 2017; 46: 738-746
        • Janssen I.
        • Shepard D.S.
        • Katzmarzyk P.T.
        • Roubenoff R.
        The healthcare costs of sarcopenia in the United States.
        J Am Geriatr Soc. 2004; 52: 80-85
        • Malmstrom T.K.
        • Morley J.E.
        SARC-F: A simple questionnaire to rapidly diagnose sarcopenia.
        J Am Med Dir Assoc. 2013; 14: 531-532
        • Malmstrom T.K.
        • Miller D.K.
        • Simonsick E.M.
        • et al.
        SARC-F: A symptom score to predict persons with sarcopenia at risk for poor functional outcomes.
        J Cachexia Sarcopenia Muscle. 2016; 7: 28-36
        • Woo J.
        • Leung J.
        • Morley J.E.
        Validating the SARC-F: A suitable community screening tool for sarcopenia?.
        J Am Med Dir Assoc. 2014; 15: 630-634
        • Parra-Rodriguez L.
        • Szlejf C.
        • Garcia-Gonzalez A.I.
        • et al.
        Cross-cultural adaptation and validation of the Spanish-language version of the SARC-F to assess sarcopenia in Mexican community-dwelling older adults.
        J Am Med Dir Assoc. 2016; 17: 1142-1146
        • Ida S.
        • Murata K.
        • Nakadachi D.
        • et al.
        Development of a Japanese version of the SARC-F for diabetic patients: An examination of reliability and validity.
        Aging Clin Exp Res. 2017; 29: 935-942
        • Barbosa-Silva T.G.
        • Menezes A.M.
        • Bielemann R.M.
        • et al.
        Enhancing SARC-F: Improving sarcopenia screening in the clinical practice.
        J Am Med Dir Assoc. 2016; 17: 1136-1141
        • Rolland Y.
        • Dupuy C.
        • Abellan Van Kan G.
        • et al.
        Sarcopenia screened by the SARC-F questionnaire and physical performances of elderly women: A cross-sectional study.
        J Am Med Dir Assoc. 2017; 18: 848-852
      1. Kim S, Kim M, Won CW. Validation of the Korean version of the SARC-F questionnaire to assess sarcopenia: Korean frailty and aging cohort study. J Am Med Dir Assoc,

        • de Vet H.C.W.
        • Eisinga A.
        • Riphagen II,
        • et al.
        Chapter 7: Searching for studies.
        in: Deeks J.J. Bossuyt P.M. Gatsonis C. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, London2008
        • Whiting P.F.
        • Rutjes A.W.
        • Westwood M.E.
        • et al.
        QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies.
        Ann Intern Med. 2011; 155: 529-536
        • Reitsma J.B.
        • Glas A.S.
        • Rutjes A.W.
        • et al.
        Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews.
        J Clin Epidemiol. 2005; 58: 982-990
        • Deeks J.J.
        • Macaskill P.
        • Irwig L.
        The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed.
        J Clin Epidemiol. 2005; 58: 882-893
        • Woo J.
        • Leung J.
        • Morley J.E.
        Defining sarcopenia in terms of incident adverse outcomes.
        J Am Med Dir Assoc. 2015; 16: 247-252
        • Yu S.C.
        • Khow K.S.
        • Jadczak A.D.
        • Visvanathan R.
        Clinical screening tools for sarcopenia and its management.
        Curr Gerontol Geriatr Res. 2016; 2016: 5978523
        • Harbord R.M.
        • Deeks J.J.
        • Egger M.
        • et al.
        A unification of models for meta-analysis of diagnostic accuracy studies.
        Biostatistics. 2007; 8: 239-251
        • Deeks J.J.
        Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests.
        BMJ. 2001; 323: 157-162
        • Grimes D.A.
        • Schulz K.F.
        Uses and abuses of screening tests.
        Lancet. 2002; 359: 881-884
        • Wu T.Y.
        • Liaw C.K.
        • Chen F.C.
        • et al.
        Sarcopenia screened with SARC-F questionnaire is associated with quality of life and 4-year mortality.
        J Am Med Dir Assoc. 2016; 17: 1129-1135
        • Churchward-Venne T.A.
        • Tieland M.
        • Verdijk L.B.
        • et al.
        There are no nonresponders to resistance-type exercise training in older men and women.
        J Am Med Dir Assoc. 2015; 16: 400-411
        • Singh N.A.
        • Quine S.
        • Clemson L.M.
        • et al.
        Effects of high-intensity progressive resistance training and targeted multidisciplinary treatment of frailty on mortality and nursing home admissions after hip fracture: A randomized controlled trial.
        J Am Med Dir Assoc. 2012; 13: 24-30
        • Tieland M.
        • Dirks M.L.
        • van der Zwaluw N.
        • et al.
        Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: A randomized, double-blind, placebo-controlled trial.
        J Am Med Dir Assoc. 2012; 13: 713-719
        • Rolland Y.
        • Onder G.
        • Morley J.E.
        • et al.
        Current and future pharmacologic treatment of sarcopenia.
        Clin Geriatr Med. 2011; 27: 423-447
        • Morley J.E.
        Hypogonadism, testosterone, and nursing home residents.
        J Am Med Dir Assoc. 2013; 14: 381-383
        • Morley J.E.
        • Vellas B.
        • van Kan G.A.
        • et al.
        Frailty consensus: A call to action.
        J Am Med Dir Assoc. 2013; 14: 392-397